TNGX news

Latest 5 stories · newest Oct 23, 2026

TNGX
Tango reports promising Phase 1/2 data for vopimetostat and daraxonrasib in pancreatic cancer

Tango Therapeutics presented significant results showing an 82% objective response rate for the vopimetostat and daraxonrasib combination in patients with metastatic pancreatic cancer. The company plans to initiate a registrational Phase 3 study in the first half of 2027.

Earnings|Guidance|M&A|Buyback|Dividend|Leadership|Restructuring|Regulatory|Legal|Cyber|Offering|Bankruptcy|Other Oct 23, 2026 sentiment +0.80 SEC filing ↗
TNGX
10 Health Care Stocks Whale Activity In Today’s Session
Options Oct 23, 2026 sentiment 0.00 Source: benzinga.com ↗
TNGX
Tango Therapeutics Appoints Robert Azelby to Board

Tango Therapeutics appointed Robert Azelby to its Board of Directors. His oncology commercialization expertise is viewed as a strategic asset as the company advances its pipeline.

Leadership Jun 23, 2026 sentiment +0.40 SEC filing ↗
TNGX
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today
Equities Jun 9, 2026 sentiment 0.00 Source: benzinga.com ↗
TNGX
Tango's vopimetostat plus daraxonrasib combo shows 92% response rate in pancreatic cancer

Tango Therapeutics announced positive Phase 1/2 data showing a combination of its PRMT5 inhibitor vopimetostat and Revolution Medicines' RAS inhibitor daraxonrasib achieved 92% objective response rate in MTAP-deleted pancreatic cancer patients, with 90% maintaining progression-free survival at 6 mon…

Regulatory Jun 8, 2026 sentiment +0.85 SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same TNGX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/TNGX/newsSTART FREE